Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

Cordier, D; Forrer, F; Bruchertseifer, F; Morgenstern, A; Apostolidis, C; Good, S; Müller-Brand, J; Mäcke, H; Reubi, J C; Merlo, A (2010). Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. European journal of nuclear medicine and molecular imaging, 37(7), pp. 1335-44. Berlin: Springer 10.1007/s00259-010-1385-5

Preview

Text Cordier2010_Article_TargetedAlpha-radionuclideTher.pdf - Published Version Available under License Publisher holds Copyright. Download (877kB) | Preview

Functionally critically located gliomas represent a challenging subgroup of intrinsic brain neoplasms. Standard therapeutic recommendations often cannot be applied, because radical treatment and preservation of neurological function are contrary goals. The successful targeting of gliomas with locally injected beta radiation-emitting (90)Y-DOTAGA-substance P has been shown previously. However, in critically located tumours, the mean tissue range of 5 mm of (90)Y may seriously damage adjacent brain areas. In contrast, the alpha radiation-emitting radionuclide (213)Bi with a mean tissue range of 81 microm may have a more favourable toxicity profile. Therefore, we evaluated locally injected (213)Bi-DOTA-substance P in patients with critically located gliomas as the primary therapeutic modality.

Interest & Impact

Downloads

51 since deposited on 04 Oct 2013
51 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item